BNP Paribas Arbitrage SA lifted its stake in shares of Codexis, Inc. (NASDAQ:CDXS) by 67,343.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,791 shares of the biotechnology company’s stock after purchasing an additional 10,775 shares during the period. BNP Paribas Arbitrage SA’s holdings in Codexis were worth $222,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of CDXS. Quantamental Technologies LLC acquired a new position in Codexis in the fourth quarter valued at approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Codexis by 152.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,837 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 1,711 shares during the last quarter. Legal & General Group Plc lifted its holdings in Codexis by 12.1% in the fourth quarter. Legal & General Group Plc now owns 9,379 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 1,010 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Codexis in the fourth quarter valued at approximately $217,000. Finally, Citigroup Inc. lifted its holdings in Codexis by 17.6% in the fourth quarter. Citigroup Inc. now owns 16,497 shares of the biotechnology company’s stock valued at $275,000 after acquiring an additional 2,471 shares during the last quarter. Institutional investors and hedge funds own 85.12% of the company’s stock.
A number of research analysts recently commented on CDXS shares. BidaskClub upgraded Codexis from a “sell” rating to a “hold” rating in a report on Friday, January 25th. ValuEngine cut Codexis from a “strong-buy” rating to a “buy” rating in a report on Monday, February 4th. Craig Hallum upped their price objective on Codexis from $20.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, February 27th. HC Wainwright upped their price objective on Codexis to $22.50 and gave the company a “buy” rating in a report on Monday, March 4th. Finally, Zacks Investment Research cut Codexis from a “hold” rating to a “sell” rating in a report on Friday, May 10th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. Codexis presently has a consensus rating of “Buy” and a consensus price target of $21.07.
Codexis (NASDAQ:CDXS) last announced its earnings results on Monday, May 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). The company had revenue of $15.58 million for the quarter, compared to analyst estimates of $14.83 million. Codexis had a negative return on equity of 21.08% and a negative net margin of 18.22%. Analysts predict that Codexis, Inc. will post -0.23 earnings per share for the current fiscal year.
In other news, Director Dennis P. Wolf sold 9,000 shares of the company’s stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $21.96, for a total transaction of $197,640.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP James Lalonde sold 19,999 shares of the stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $18.65, for a total value of $372,981.35. The disclosure for this sale can be found here. In the last three months, insiders sold 164,071 shares of company stock worth $3,388,171. 10.70% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2019/05/25/bnp-paribas-arbitrage-sa-buys-10775-shares-of-codexis-inc-cdxs.html.
Codexis Company Profile
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS).
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.